FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3097152062> ?p ?o ?g. }

• W3097152062 endingPage "36" @default.
• W3097152062 startingPage "36" @default.
• W3097152062 abstract "Introduction: MPN are a heterogeneous group of chronic hematological malignancies often resulting from a combination of a driver gene mutation (JAK2, MPL or CALR) and a variety of somatic mutations harboring diverse prognosis values. A subset of MPN patients carry somatic mutations in the hematopoietic transcription factor NFE2 (nuclear factor erythroid 2) resulting in a functionally enhanced truncated form of NFE2 (Jutzi JS et al., JEM, 2013). Moreover, epigenetically induced overexpression of NFE2 has recently been reported in the majority of MPN patients (Peeken JC et al., Blood, 2018). In transgenic murine models, NFE2 overexpression results in an MPN phenotype (thrombocytosis, leukocytosis, EPO-independent colony formation, characteristic bone marrow histology and expansion of stem and progenitor compartments) and has recently been shown to predispose to the acquisition of additional genetic abnormalities and subsequent leukemic transformation (Kaufmann KB et al., JEM, 2012) (Jutzi JS et al., Blood, 2019). However, clinical impact of NFE2 mutations in MPN patients remains unknown. The aim of this study was to evaluate the phenotypic characteristics and prognostic impact of NFE2 somatic mutations in a large mono-centric cohort of MPN patients. Methods: A total of 1243 consecutive patients were diagnosed with MPN according to WHO criteria and followed in our hospital between January 2011 and May 2020. This study included 707 of them in whom a next-generation sequencing (NGS) molecular analysis targeting 36 myeloid genes was performed at diagnosis and/or during follow-up. Clinical and biological characteristics at time of diagnosis and follow-up were collected from medical charts and electronic medical records. Statistical analyses were performed using the STATA software (STATA 15.0 Corporation, College Station, TX). Results: In our cohort, 411 patients presented with polycythemia vera (PV), 577 with essential thrombocythemia (ET), 184 with primary or pre-fibrotic myelofibrosis (PMF), 59 with unclassified MPN and 12 with MDS/MPN. Median age at diagnosis was 51 years [40-63]. 73.1% patients had a JAK2V617F mutation, 14.1% a CALR mutation and 3.3% a MPL mutation. Overall, 64 (9.05%) patients harbored a NFE2 mutation with a variant allelic frequency (VAF) ≥ 0.5% and 36 had a VAF ≥ 5%, the latest were considered as NFE2 mutated for the rest of the study as VAF &lt;5% may refer to a minor clone without clinical relevance. NFE2 mutations were present in 7.3%, 5.3% and 3.6% of PV, PMF and ET patients respectively. No significant association between the presence of NFE2 mutation and clinical/molecular MPN characteristics (driver mutation, constitutional symptoms, splenomegaly, blood counts, cytogenetic and other molecular features) was observed using a logistic regression association model. Median follow-up was 103.8 months, IQR [47.2; 175.6]. In terms of response to therapy, 52.8% of patients achieved complete response, complete hematological response or clinical improvement in NFE2 mutated vs 61.7% in non-mutated patients (p= 0.026). Interestingly, presence of a NFE2 mutation (HR 9.92, 95%CI[3.21; 30.64], p&lt; 0.001), age at diagnosis (HR 1.09, 95%CI[1.05; 1.12], p&lt; 0.001), PMF subtype (HR 6.92, 95%CI[2.81; 17.06], p &lt; 0.001) and high-risk mutations (ASXL1, EZH2, SRSF2, IDH1/2 and U2AF1) (HR 2.45, 95%CI[1.14; 5.28], p=0.021) were independently associated with AML/MDS transformation free survival (TFS) in a COX regression multivariate analysis (Figure A). Presence of a NFE2 mutation was also independently associated with overall survival (OS) (HR 9.37, 95%CI [4.18; 21.03], p&lt;0.001) (Figure B). Median TFS were 216.1 months and not reached, while median OS were 144.2 months and not reached for NFE2 mutated and non-mutated patients, respectively. No difference was observed in terms of thrombo-hemorrhagic events (HR 0.73; 95%CI [0.10; 5.21], p=0.752) and secondary myelofibrosis free survivals (HR 0.67; 95%CI [0.09; 4.87], p=0.693). Conclusion: In this retrospective study we show that presence of NFE2 mutations with a VAF ≥5% is independently associated with an increased risk of leukemic transformation and shorter overall survival. These findings are in line with recently reported animal models and suggest that NFE2 mutations screening should be routinely performed in MPN patients. Disclosures Rea: Incyte: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees. Kiladjian:AOP Orphan: Membership on an entity's Board of Directors or advisory committees; AbbVie: Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees. Benajiba:Gilead Foundation: Research Funding." @default.
• W3097152062 created "2020-11-09" @default.
• W3097152062 creator A5001904545 @default.
• W3097152062 creator A5008609620 @default.
• W3097152062 creator A5013742740 @default.
• W3097152062 creator A5014090815 @default.
• W3097152062 creator A5040833467 @default.
• W3097152062 creator A5041595893 @default.
• W3097152062 creator A5041669113 @default.
• W3097152062 creator A5049350912 @default.
• W3097152062 creator A5054338359 @default.
• W3097152062 creator A5055797334 @default.
• W3097152062 creator A5059057760 @default.
• W3097152062 creator A5063153979 @default.
• W3097152062 creator A5064103067 @default.
• W3097152062 creator A5068871851 @default.
• W3097152062 creator A5078437874 @default.
• W3097152062 creator A5081008172 @default.
• W3097152062 creator A5081977456 @default.
• W3097152062 creator A5083553066 @default.
• W3097152062 date "2020-11-05" @default.
• W3097152062 modified "2023-09-30" @default.
• W3097152062 title "NFE2 Mutations Impact AML Transformation and Overall Survival in Patients with Myeloproliferative Neoplasms (MPN)" @default.
• W3097152062 doi "https://doi.org/10.1182/blood-2020-136177" @default.
• W3097152062 hasPublicationYear "2020" @default.
• W3097152062 type Work @default.
• W3097152062 sameAs 3097152062 @default.
• W3097152062 citedByCount "0" @default.
• W3097152062 crossrefType "journal-article" @default.
• W3097152062 hasAuthorship W3097152062A5001904545 @default.
• W3097152062 hasAuthorship W3097152062A5008609620 @default.
• W3097152062 hasAuthorship W3097152062A5013742740 @default.
• W3097152062 hasAuthorship W3097152062A5014090815 @default.
• W3097152062 hasAuthorship W3097152062A5040833467 @default.
• W3097152062 hasAuthorship W3097152062A5041595893 @default.
• W3097152062 hasAuthorship W3097152062A5041669113 @default.
• W3097152062 hasAuthorship W3097152062A5049350912 @default.
• W3097152062 hasAuthorship W3097152062A5054338359 @default.
• W3097152062 hasAuthorship W3097152062A5055797334 @default.
• W3097152062 hasAuthorship W3097152062A5059057760 @default.
• W3097152062 hasAuthorship W3097152062A5063153979 @default.
• W3097152062 hasAuthorship W3097152062A5064103067 @default.
• W3097152062 hasAuthorship W3097152062A5068871851 @default.
• W3097152062 hasAuthorship W3097152062A5078437874 @default.
• W3097152062 hasAuthorship W3097152062A5081008172 @default.
• W3097152062 hasAuthorship W3097152062A5081977456 @default.
• W3097152062 hasAuthorship W3097152062A5083553066 @default.
• W3097152062 hasBestOaLocation W30971520621 @default.
• W3097152062 hasConcept C109159458 @default.
• W3097152062 hasConcept C126322002 @default.
• W3097152062 hasConcept C143998085 @default.
• W3097152062 hasConcept C2778923028 @default.
• W3097152062 hasConcept C2779282312 @default.
• W3097152062 hasConcept C2779788118 @default.
• W3097152062 hasConcept C28328180 @default.
• W3097152062 hasConcept C502942594 @default.
• W3097152062 hasConcept C54355233 @default.
• W3097152062 hasConcept C71924100 @default.
• W3097152062 hasConcept C86803240 @default.
• W3097152062 hasConcept C89560881 @default.
• W3097152062 hasConceptScore W3097152062C109159458 @default.
• W3097152062 hasConceptScore W3097152062C126322002 @default.
• W3097152062 hasConceptScore W3097152062C143998085 @default.
• W3097152062 hasConceptScore W3097152062C2778923028 @default.
• W3097152062 hasConceptScore W3097152062C2779282312 @default.
• W3097152062 hasConceptScore W3097152062C2779788118 @default.
• W3097152062 hasConceptScore W3097152062C28328180 @default.
• W3097152062 hasConceptScore W3097152062C502942594 @default.
• W3097152062 hasConceptScore W3097152062C54355233 @default.
• W3097152062 hasConceptScore W3097152062C71924100 @default.
• W3097152062 hasConceptScore W3097152062C86803240 @default.
• W3097152062 hasConceptScore W3097152062C89560881 @default.
• W3097152062 hasIssue "Supplement 1" @default.
• W3097152062 hasLocation W30971520621 @default.
• W3097152062 hasOpenAccess W3097152062 @default.
• W3097152062 hasPrimaryLocation W30971520621 @default.
• W3097152062 hasRelatedWork W2092147087 @default.
• W3097152062 hasRelatedWork W2140669766 @default.
• W3097152062 hasRelatedWork W2384178491 @default.
• W3097152062 hasRelatedWork W2409154575 @default.
• W3097152062 hasRelatedWork W2425971861 @default.
• W3097152062 hasRelatedWork W2562937924 @default.
• W3097152062 hasRelatedWork W2613883645 @default.
• W3097152062 hasRelatedWork W2807123812 @default.
• W3097152062 hasRelatedWork W2891888128 @default.
• W3097152062 hasRelatedWork W98326741 @default.
• W3097152062 hasVolume "136" @default.
• W3097152062 isParatext "false" @default.
• W3097152062 isRetracted "false" @default.
• W3097152062 magId "3097152062" @default.
• W3097152062 workType "article" @default.